Navigation Links
Reportlinker Adds Gene Therapy - technologies, markets and companies

NEW YORK, Dec. 21, 2010 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Gene Therapy - technologies, markets and companies

Benefits of this report- Up-to-date on-stop information on gene therapy with 72 tables and 13 figures

- Evaluation of gene therapy technologies

- 700 selected references from the literature

- Estimates of gene therapy markets from 2009-2019

- Profiles of 189 companies involved and collaborations in this area

Who should read this report?- Biotechnology companies developing gene therapy

- Academic institutions doing research in gene therapy

- Drug delivery companies

- Pharmaceutical companies interested in gene therapy

- Gene therapy companies

- Venture capital and investment companies

SummaryGene therapy can be broadly defined as the transfer of defined genetic material to specific target cells of a patient for the ultimate purpose of preventing or altering a particular disease state. Genes and DNA are now being introduced without the use of vectors and various techniques are being used to modify the function of genes in vivo without gene transfer. If one adds to this the cell therapy particularly with use of genetically modified cells, the scope of gene therapy becomes much broader. Gene therapy can now combined with antisense techniques such as RNA interference (RNAi), further increasing the therapeutic applications. This report takes broad overview of gene therapy and is the most up-to-date presentation from the author on this topic built-up from a series of gene therapy report written by him during the past decade including a textbook of gene therapy and a book on gene therapy companies. This report describes the setbacks of gene therapy and renewed interest in the topic

Gene therapy technologies are described in detail including viral vectors, nonviral vectors and cell therapy with genetically modified vectors. Gene therapy is an excellent method of drug delivery and various routes of administration as well as targeted gene therapy are described. There is an introduction to technologies for gene suppression as well as molecular diagnostics to detect and monitor gene expression.

Clinical applications of gene therapy are extensive and cover most systems and their disorders. Full chapters are devoted to genetic syndromes, cancer, cardiovascular diseases, neurological disorders and viral infections with emphasis on AIDS. Applications of gene therapy in veterinary medicine, particularly for treating cats and dogs, are included.

Research and development is in progress in both the academic and the industrial sectors. The National Institutes of Health (NIH) of the US is playing an important part. As of January 2010, over 2024 gene therapy clinical trials have been completed, are ongoing or have been approved worldwide. A breakdown of these trials is shown according to the areas of application.

Since the death of Jesse Gelsinger in the US following a gene therapy treatment, the FDA has further tightened the regulatory control on gene therapy. A further setback was the reports of leukemia following use of retroviral vectors in successful gene therapy for adenosine deaminase deficiency. Several clinical trials were put on hold and many have resumed now. The report also discusses the adverse effects of various vectors, safety regulations and ethical aspects of gene therapy including germline gene therapy.

The markets for gene therapy are difficult to estimate as there is only one approved gene therapy product and it is marketed in China since 2004. Gene therapy markets are estimated for the years 2009-2019. The estimates are based on epidemiology of diseases to be treated with gene therapy, the portion of those who will be eligible for these treatments, competing technologies and the technical developments anticipated in the next decades. In spite of some setbacks, the future for gene therapy is bright. The markets for DNA vaccines are calculated separately as only genetically modified vaccines and those using viral vectors are included in the gene therapy markets

The voluminous literature on gene therapy was reviewed and selected 700 references are appended in the bibliography. The references are constantly updated. The text is supplemented with 72 tables and 13 figures.

Profiles of 189 companies involved in developing gene therapy are presented along with 210 collaborations. There were only 44 companies involved in this area in 1995. In spite of some failures and mergers, the number of companies has increased more than 4-fold within a decade. These companies have been followed up since they were the topic of a book on gene therapy companies by the author of this report. John Wiley & Sons published the book in 2000 and from 2001 to 2003, updated versions of these companies (approximately 160 at mid-2003) were available on Wiley's web site. Since that free service was discontinued and the rights reverted to the author, this report remains the only authorized continuously updated version on gene therapy companies.

Table of Contents

0. Executive Summary 19

1. Introduction 21

Definitions 21

Historical evolution of gene therapy 21

Relation of gene therapy to other biotechnologies 23

Molecular biological basics for gene therapy 23

Genome 23

DNA 24

RNA 24

Alternative RNA splicing 25

Genes 26

Gene regulation 26

Gene expression 28

Chromosomes 28

Telomeres 29

Mitochondrial DNA 29

Proteins 30

2. Gene Therapy Technologies 31

Classification of gene therapy techniques 31

Ex vivo and in vivo gene therapy 32

Ex vivo gene therapy 32

In vivo gene therapy 33

Physical methods of gene transfer 33

Electroporation 33

Applications of electroporation 34

Clinical applications of electroporation 35

Advantages of electroporation 35

Limitations of electroporation 36

Hydrodynamic 36

Microinjection 36

Particle bombardment 37

Ultrasound-mediated transfection 39

Molecular vibration 40

Application of pulsed magnetic field and superparamagnetic nanoparticles 40

Gene transfection using laser irradiation 40

Photochemical transfection 41

Chemical methods of gene transfer 41

Gene repair and replacement 41

Gene repair by single-stranded oligonucleotides 42

History and current status of chimeraplasty 42

mRNA gene therapy 42

Spliceosome mediated RNA trans-splicing 43

Vectors for gene therapy 44

Basic considerations 44

Use of genes as pharmaceuticals 44

The ideal vector for gene therapy 45

Viral vectors 45

Adenovirus vectors 46

Adeno-associated virus vectors 48

Alphavirus vectors 50

Baculovirus vectors 50

Foamy virus vectors 51

Herpes simplex virus vectors 51

Lentiviral vectors 53

Multicistronic retroviral vectors 54

Retroviral vectors 55

Oncogenic potential of retroviral vectors 56

Future prospects of viral vectors 57

Companies using viral vectors 57

Nonviral vectors for gene therapy 59

Anionic lipid-DNA complexes 59

Cationic lipid-DNA complexes 60

Effects of shape of DNA molecules on delivery with nonviral vectors 60

Electrostatic modifications of surface to improve gene delivery 60

Liposomes for gene therapy 61

Liposome-nucleic acid complexes 62

Liposome-HVJ complex 63

Transposons DNA vectors 63

Polycation-DNA complexes (polyplexes) 64

Plasmid DNA vector for treatment of chronic inflammatory disease 65

Polymer molecules 65

Synthetic biology and DNA vectors 65

Synthetic peptide complexes 66

Future prospects of nonviral vs viral vectors 66

Nanobiotechnology for gene therapy 66

Antisense nanoparticles for gene regulation 67

Biological nanoparticle technology 67

Dendrimers 67

Cochleates 67

Calcium phosphate nanoparticles as nonviral vectors 68

Gelatin nanoparticles for gene delivery 68

Lipid nanoparticles for nucleic acid delivery 69

Nanoparticles as nonviral vectors for gene therapy 69

Nanoparticles with virus-like function as gene therapy vectors 70

Nonionic polymeric micelles for oral gene delivery 70

Silica nanoparticles as a nonviral vector for gene delivery 70

Receptor-mediated endocytosis 71

Artificial viral vectors 72

Directed evolution of AAV to create efficient gene delivery vectors 72

Bacterial ghosts as DNA delivery systems 73

Bacteria plus nanoparticles for gene delivery into cells 73

Chromosome-based vectors for gene therapy 74

Companies using nonviral vectors 76

Concluding remarks about vectors 77

Cell-mediated gene therapy 78

Fibroblasts 78

Skeletal muscle cells 79

Vascular smooth muscle cells 79

Keratinocytes 80

Hepatocytes 80

Lymphocytes 80

Regulating protein delivery by genetically encoded lymphocytes 81

Implantation of microencapulated genetically modified cells 81

Stem cell gene therapy 82

Therapeutic applications for hematopoietic stem cell gene transfer 82

Improving delivery of genes to stem cells 82

Lentiviral vectors for gene transfer to marrow stem cells 82

Use of mesenchymal stem cells for gene therapy 83

Microporation for transfection of MSCs 83

In utero gene therapy using stem cells 83

Gene delivery to stem cells by artificial chromosome expression 83

Linker based sperm-mediated gene transfer technology 84

Combination of gene therapy with therapeutic cloning 84

Expansion of transduced HSCs in vivo 84

The future of hematopoietic stem cell gene therapy 85

Routes of administration for gene therapy 85

Direct injection of naked DNA 85

Intramuscular injection 86

Intravenous DNA injection 86

Intraarterial delivery 86

Companies with gene delivery devices/ technologies 86

Targeted gene therapy 88

Targeted integration 88

Bacteriophage integrase system for site-specific gene delivery 88

Controlled-release delivery of DNA 89

Controlled gene therapy 89

Controlled delivery of genetic material 89

Controlled induction of gene expression 90

Drug-inducible systems for control of gene expression 90

Timed activation of gene therapy by a circuit based on signaling network 91

Small molecules for post-transcriptional regulation of gene expression 91

Engineered zinc finger DNA binding proteins for gene correction 92

Light Activated Gene Therapy 92

Spatial control of gene expression via local hyperthermia 92

Companies with regulated /targeted gene therapy 92

Gene marking 94

Germline gene therapy 94

Potential applications of human germline genome modification 94

Pros and cons of human germline genome modification 95

Role of gene transfer in antibody therapy 96

Genetically engineered vaccines 96

DNA vaccines 96

DNA inoculation technology 97

Methods for enhancing the potency of DNA vaccines 97

Advantages of DNA vaccines 98

Vaccine vectors 98

Challenges and limitations of genetically engineered vaccines 99

Vaccines based on reverse genetics 100

Technologies for gene suppression 100

Antisense oligonucleotides 100

Transcription factor decoys 101

Aptamers 101

Ribozymes 102

Peptide nucleic acid 102

Intracellular delivery of PNAs 102

Locked nucleic acid 103

Zorro-LNA 103

Gene silencing 103

Post-transcriptional gene silencing 103

Definitions and terminology of RNAi 104

RNAi mechanisms 104

Inhibition of gene expression by antigene RNA 105

RNAi gene therapy 106

Application of molecular diagnostic methods in gene therapy 106

Use of PCR to study biodistribution of gene therapy vector 106

PCR for verification of the transcription of DNA 107

In situ PCR for direct quantification of gene transfer into cells 107

Detection of retroviruses by reverse transcriptase (RT)-PCR 107

Confirmation of viral vector integration 107

Monitoring of gene expression 108

Monitoring of gene expression by green fluorescent protein 108

Monitoring in vivo gene expression by molecular imaging 108

Advantages of gene therapy compared with protein therapy 108

3. Clinical Applications of Gene Therapy 111

Introduction 111

Bone and joint disorders 111

Bone fractures 111

Gene therapy for intervertebral disc degeneration 112

Spinal fusion 112

Osteogenesis imperfecta 113

Rheumatoid arthritis 113

Local or systemic treatment 114

In vivo or ex vivo gene therapy of RA 114

Clinical trials 115

Gene therapy for osteoarthritis 116

Sports injuries 117

Repair of articular cartilage defects 117

Regeneration and replacement of bone by gene therapy 118

Bacterial infections 119

Antisense approach to bacterial infections 119

Dentistry 119

Tissue engineering in dental implant defects 119

Endocrine and metabolic disorders 120

Introduction 120

Gene therapy of obesity 120

Ad viral vector-mediated transfer of leptin gene 120

AAV vector-mediated delivery of GDNF for obesity 121

Diabetes mellitus 121

Methods of gene therapy of diabetes mellitus 121

Viral vector-mediated gene transfer in diabetes 122

Gene delivery with ultrasonic microbubble destruction technology 123

Genetically engineered cells for diabetes mellitus 123

Genetically altered liver cells 123

Genetically modified stem cells 124

Genetically engineered dendritic cells 124

Insertion of gene encoding for IL-4 124

Leptin gene therapy 125

Concluding remarks about cell and gene therapy of diabetes 125

Gene therapy of growth-hormone deficiency 125

Gastrointestinal disorders 126

Introduction 126

Methods of gene transfer to the gastrointestinal tract 127

Direct delivery of genes 127

Naked plasmid DNA into the submucosa 127

Viral vectors 127

Receptor-mediated endocytosis 127

Indications for gastrointestinal gene therapy 128

Gene therapy for inflammatory disorders of the bowel 128

Gene transfer to the salivary glands 129

Potential clinical applications of salivary gene therapy 129

Hematology 130

Hemophilias 130

Gene therapy of hemophilia 131

Hemophilia A 131

Hemophilia B 132

Concluding remarks about gene therapy of hemophilias 133

Hemoglobinopathies 133

Stem cell-based gene therapy and RNAi for sickle cell disease 133

Gene therapy for b-thalassemia 134

Gene therapy of Fanconi's anemia 135

Acquired hematopoietic disorders 136

Chronic acquired anemias 136

Neutropenia 137

Thrombocytopenia 137

Concluding remarks about gene therapy of hemoglobinopathies 138

Companies involved in gene therapy of hematological disorders 139

In utero gene therapy 139

Fetal gene transfer techniques 139

Animal models of fetal gene therapy 140

Potential applications of fetal gene therapy 140

Fetal gene therapy for cystic fibrosis 141

Fetal intestinal gene therapy 141

Hearing disorders 141

Potential of gene therapy 142

Vectors for gene therapy of hearing disorders 142

Auditory hair cell replacement and hearing improvement by gene therapy 143

Kidney diseases 143

End-stage renal disease 143

Methods of gene delivery to the kidney 144

Gene transfer into kidney by adenoviral vectors 144

Non-viral gene transfer to the kidneys 144

Gene transfer into the glomerulus by HVJ-liposome 145

Bone marrow stem cells for renal disease 145

Mesangial cell therapy 145

Liposome-mediated gene transfer into the tubules 146

Gene transfer to tubules with cationic polymer polyethylenimine 146

Gene therapy in animal experimental models of renal disease 146

Genetic manipulations of the embryonic kidney 147

Antisense intervention in glomerulonephritis 147

Gene therapy for renal fibrosis 147

Use of genetically engineered cells for uremia due to renal failure 148

Concluding remarks 148

Liver disorders 148

Techniques of gene delivery to liver 149

Direct injection of DNA into liver 149

Local gene delivery by isolated organ perfusion 150

Liposome-mediated direct gene transfer 150

Retroviral vector for gene transfer to liver 150

Adenoviral vectors for gene transfer to liver 150

Receptor-mediated approach 151

Cell therapy for liver disorders 151

Transplantation of genetically modified hepatocytes 151

Genetically modified hematopoietic stem cells 152

Gene therapy by ex vivo transduced liver progenitor cells 152

Gene therapy of genetic diseases affecting the liver 152

Crigler-Najjar syndrome 152

Hereditary tyrosinemia type I (HT1) 153

Hereditary tyrosinemia type 3 153

Gene therapy of acquired diseases affecting the liver 153

Cirrhosis of liver 153

Ophthalmic disorders 154

Introduction to gene therapy of ophthalmic disorders 154

Degenerative retinal disorders 155

Age-related macular degeneration 155

Inherited retinal degenerations 156

Inherited disorders affecting vision 157

Gene therapy for color blindness 157

Leber congenital amaurosis 157

Retinitis pigmentosa 158

Stargardt disease 159

Usher syndrome 159

X-linked juvenile retinoschisis 160

Proliferative retinopathies 160

Methods of gene transfer to retinal cells 160

DNA nanoparticles for nonviral gene transfer to the eye 161

Prevention of complications associated with eye surgery 162

Prevention of proliferative retinopathy by gene therapy 162

DNA nanoparticles for gene therapy of retinal degenerative disorders 162

Posterior capsule opacification after cataract surgery 162

Autoimmune uveitis 162

Retinal ischemic injury 163

Corneal disorders 163

Glaucoma 164

Disorders of hearing 164

Gene therapy for hearing loss 164

Organ transplantation 165

Introduction 165

DNA vaccines for transplantation 165

Gene therapy for prolonging allograft survival 165

Gene therapy in lung transplantation 166

Role of gene therapy in liver transplantation 166

Gene therapy in kidney transplantation 166

Veto cells and transplant tolerance 167

Pulmonary disorders 167

Techniques of gene delivery to the lungs 168

Adenoviral vectors 168

Non-viral vectors 169

Aerosolization as an aid to gene transfer to lungs. 169

Cystic fibrosis 170

Genetics and clinical features 170

Gene therapy for CF 170

CFTR gene transfer in CF 170

Concluding remarks about gene therapy of CF 172

Miscellaneous pulmonary disorders 172

Gene therapy for pulmonary arterial hypertension 172

Gene therapy for bleomycin-induced pulmonary fibrosis 173

Pulmonary complications of a1-antitrypsin deficiency 173

Gene therapy for asthma 174

Gene therapy for adult respiratory distress syndrome 175

Gene therapy for lung injury 175

Gene therapy for bronchopulmonary dysplasia 175

Concluding remarks about gene therapy of lungs 176

Companies involved in pulmonary gene therapy 176

Skin and soft tissue disorders 177

Gene transfer to the skin 177

Electroporation for transdermal delivery of plasmid DNA 177

Electroporation for transdermal delivery of DNA vaccines 178

Liposomes for transdermal gene delivery 178

Ultrasound and topical gene therapy 178

Gene therapy in skin disorders 178

Gene therapy of hair loss 179

Gene therapy for xeroderma pigmentosa 179

Gene therapy for lamellar ichthyosis 179

Gene therapy for epidermolysis bullosa 180

Gene transfer techniques for wound healing 180

Urogenital disorders 181

Gene therapy for urinary tract dysfunction 181

Gene therapy for erectile dysfunction 181

NOS gene transfer for erectile dysfunction 181

Clinical trial of hMaxi-K Gene transfer in erectile dysfunction 182

Gene therapy for erectile dysfunction due to nerve injury 182

Concluding remarks on gene therapy for erectile dysfunction 182

Veterinary gene therapy 183

Gene therapy for mucopolysaccharidosis VII in dogs 183

Gene therapy to increase disease resistance 183

Gene therapy for infections 184

Gene therapy for chronic anemia 184

Gene therapy for endocrine disorders 185

Gene therapy for arthritis 185

Cancer gene therapy 185

Brain tumors in cats and dogs 185

Breast cancer in dogs 186

Canine hemangiosarcoma 187

Canine melanoma 187

Canine soft tissue sarcoma 187

Melanoma in horses 188

4. Gene Therapy of Genetic Disorders 189

Introduction 189

Primary immunodeficiency disorders 190

Severe combined immune deficiency 191

Chronic granulomatous disease 193

Wiskott-Aldrich syndrome 193

Purine nucleoside phosphorylase deficiency 194

Major histocompatibility class II deficiency 194

Future prospects of gene therapy of inherited immunodeficiencies 195

Metabolic disorders 195

Adrenoleukodystrophy 196

Canavan disease 196

Lesch-Nyhan syndrome 197

Ornithine transcarbamylase deficiency 197

Phenylketonuria 198

Porphyrias 198

Tetrahydrobiopterin deficiency 199

Lysosomal storage disorders. 199

Batten disease 200

Fabry's disease 201

Farber's disease 201

Gaucher disease 202

Animals models of Gaucher's disease 202

Gene therapy of Gaucher's disease 202

Hunter syndrome 203

Combination of cell and gene therapy for Krabbe's disease 203

Metachromatic leukodystrophy 204

Mucopolysaccharidosis type 1 (Hurler syndrome) 205

Niemann-Pick type A disease 205

Pompe disease 205

Sanfilippo A syndrome 206

Sly syndrome 206

Tay-Sachs disease 207

Future prospects of gene therapy of lysosomal storage disorders 207

Trinucleotide repeat disorders 207

Muscular dystrophies 208

Duchenne muscular dystrophy (DMD) 208

Animal models for gene therapy of DMD 208

Antisense approach to DMD 208

Liposome-mediated gene transfer 209

Myoblast-based gene transfer in DMD 210

Plasmid-mediated gene therapy 210

Post-transcriptional modulation of gene expression in DMD 210

Repair of dystrophin gene 211

Routes of administration of gene therapy in DMD 211

Types of dystrophin constructs 211

Viral vectors for DMD 212

Conclusions and future prospects of gene therapy of DMD 213

Limb-girdle muscular dystrophy 214

Myotonic dystrophy 214

Spinal muscular atrophy 215

Antisense gene therapy of SMA 215

Hereditary neuropathies 215

Charcot-Marie-Tooth disease 215

Hereditary axonal neuropathies of the peripheral nerves 216

Gene therapy of mitochondrial disorders 216

Companies involved in gene therapy of genetic disorders 217

5. Gene Therapy of Cancer 219

Strategies for cancer gene therapy 219

Direct gene delivery to the tumor 220

Injection into tumor 220

Direct injection of adenoviral vectors 220

Direct injection of a plasmid DNA-liposome complex 221

A polymer approach to local gene therapy for cancer 221

Electroporation for cancer gene therapy 221

Control of gene expression in tumor by local heat 222

Radiation-guided gene therapy of cancer 222

Nanoparticles to facilitate combination of hyperthermia and gene therapy 223

Cell-based cancer gene therapy 223

Adoptive cell therapy 223

Cytokine gene therapy 224

Genetic modification of human hematopoietic stem cells 227

Immunogene therapy 227

Cancer vaccines 228

Genetically modified cancer cell vaccines 228

GVAX cancer vaccines 228

Genetically modified dendritic cells 229

Nucleic acid-based cancer vaccines 229

DNA cancer vaccines 230

RNA vaccines 230

Viral vector-based cancer vaccines 230

Intradermal delivery of cancer vaccines by Ad vectors 231

Future prospects of cancer vaccines 231

Companies involved in nucleic acid-based cancer vaccines 231

Monoclonal antibody gene transfer for cancer 232

Transfer and expression of intracellular adhesion-1 molecules 233

Other gene-based techniques of immunotherapy of cancer 233

Fas (Apo-1) 233

Chemokines 233

Major Histocompatibility Complex (MHC) Class I 234

IGF (Insulin-Like Growth Factor) 234

Inhibition of immunosuppressive function in cancer 234

Delivery of toxic genes to tumor cells for eradication 235

Gene-directed enzyme prodrug therapy 235

Combination of gene therapy with radiotherapy 235

Correction of genetic defects in cancer cells 236

Targeted gene therapy for cancer 236

Antiangiogenic therapy for cancer 236

Bacteria as novel anticancer gene vectors 237

Cancer-specific gene expression 238

Cancer-specific transcription 238

Delivery of retroviral particles hitchhiking on T cells 238

Electrogene and electrochemotherapy 239

Epidermal growth factor-mediated DNA delivery 239

Gene-based targeted drug delivery to tumors 239

Gene expression in hypoxic tumor cells 240

Genetically modified T cells for targeting tumors 240

Genetically engineered stem cells for targeting tumors 241

Hematopoietic stem cells for targeted cancer gene therapy 242

Immunolipoplex for delivery of p53 gene 242

Nanomagnets for targeted cell-based cancer gene therapy 243

Nanoparticles for targeted site-specific delivery of anticancer genes 243

Targeted cancer therapy using a dendrimer-based synthetic vector 243

Tumor-targeted gene therapy by receptor-mediated endocytosis 244

Virus-mediated oncolysis 244

Targeted cancer treatments based on oncolytic viruses 244

Oncolytic HSV 244

Oncolytic adenoviruses 245

Oncolytic vesicular stomatitis virus 246

Oncolytic paramyxovirus 246

Oncolytic vaccinia virus 247

Cancer terminator virus 247

Cytokine-induced killer cells for delivery of an oncolytic virus 248

Monitoring of viral-mediated oncolysis by PET 248

Oncolytic gene therapy 248

Companies developing oncolytic viruses 249

Apoptotic approach to improve cancer gene therapy 249

Tumor suppressor gene therapy 250

P53 gene therapy 250

BRIT1 gene therapy 250

Nitric oxide-based cancer gene therapy 251

Nitric oxide synthase II DNA injection 251

Gene therapy for radiosensitization of cancer 251

Gene therapy of cancer of selected organs 251

Gene therapy for bladder cancer 251

Gene therapy for glioblastoma multiforme. 252

Targeted adenoviral vectors 253

Genetically engineered MSCs for gene delivery to intracranial gliomas 254

Targeting normal brain cells with an AAV vector encoding interferon-b 254

Viral oncolysis of brain tumors 254

Autophagy induced by conditionally replicating adenoviruses 255

Oncolytic virus targeted to brain tumor stem cells 255

Antiangiogenic gene therapy 256

Baculovirus vector for diphtheria toxin gene therapy 256

Intravenous gene delivery with nanoparticles into brain tumors 256

Gene therapy targeting hepatocyte growth factor 257

RNAi gene therapy of brain cancer 257

Ligand-directed delivery of dsRNA molecules targeted to EGFR 257

Gene therapy for breast cancer 258

Gene vaccine for breast cancer 258

Recombinant adenoviral ErbB-2/neu vaccine 259

Gene Therapy for ovarian cancer 259

Gene therapy for malignant melanoma 260

Gene therapy of lung cancer 262

Intravenous nanoparticle formulation for delivery of FUS1 gene 262

Aerosol gene delivery for lung cancer 263

Gene therapy for cancer of prostate 263

Experimental studies 263

Nanoparticle-based gene therapy for prostate cancer 263

Tumor suppressor gene therapy in prostate cancer 264

Vaccines for prostate cancer 264

Clinical trials 264

Gene therapy of head and neck cancer 265

Adenoviral vector based P53 gene therapy 265

Gene therapy of pancreatic cancer 265

Rexin-GO for targeted gene delivery in cancer 266

Targeted Expression of BikDD gene 266

Concluding remarks on gene therapy of pancreatic cancer 266

Cancer gene therapy companies 267

6. Gene Therapy of Neurological Disorders 271

Indications 271

Gene transfer techniques for the nervous system 272

Methods of gene transfer to the nervous system 272

Ideal vector for gene therapy of neurological disorders 272

Promoters of gene transfer 272

Lentivirus-mediated gene transfer to the CNS 273

AAV vector mediated gene therapy for neurogenetic disorders 273

Gene transfer to the CNS using recombinant SV40-derived vectors 274

Routes of delivery of genes to the CNS 274

Direct injection into CNS 274

Introduction of the genes into cerebral circulation 275

Introduction of genes into cerebrospinal fluid 275

Intravenous administration of vectors 275

Delivery of gene therapy to the peripheral nervous system 276

Cell-mediated gene therapy of neurological disorders 276

Neuronal cells 276

Neural stem cells and progenitor cells 276

Astrocytes 276

Cerebral endothelial cells 277

Implantation of genetically modified encapsulated cells into the brain 277

Gene therapy of neurodegenerative disorders 277

Gene therapy for Parkinson disease 277

Rationale 278

Techniques of gene therapy for PD 279

Delivery of neurotrophic factors by gene therapy 282

Delivery of parkin gene 283

Introduction of functional genes into the brain of patients with PD 283

Nanoparticle-based gene therapy for PD 283

Mitochondrial gene therapy for PD 283

RNAi approach to PD 284

Prospects of gene therapy for PD 284

Companies developing gene therapy for PD 285

Gene therapy for Alzheimer disease 286

Rationale 286

NGF gene therapy for AD 286

Neprilysin gene therapy 287

Targeting plasminogen activator inhibitor type-1 gene 288

Gene vaccination 288

Combination of gene therapy with other treatments for AD 288

Gene therapy of Huntington disease 289

Encapsulated genetically engineered cellular implants 289

Viral vector mediated administration of neurotrophic factors 289

RNAi gene therapy 289

Gene therapy of amyotrophic lateral sclerosis 290

Rationale 290

Technique of gene therapy of ALS 290

Gene therapy of cerebrovascular diseases 291

Preclinical research in gene therapy for cerebrovascular disease 291

Animal models of stroke relevant to gene therapy 291

Transgenic mice as models for stroke 292

Animal models for gene therapy of arteriovenous malformations 292

Gene transfer to cerebral blood vessels 292

Gene therapy for vasospasm following subarachnoid hemorrhage 293

NOS gene therapy for cerebral vasospasm 294

Gene therapy for stroke 294

Gene therapy for stroke using neurotrophic factors 296

Gene therapy of strokes with a genetic component 296

Gene therapy for intracranial aneurysms 296

Concluding remarks about gene therapy for stroke 296

Gene therapy of injuries to the nervous system 297

Traumatic brain injury 297

Spinal cord injury 297

Gene therapy of epilepsy 298

Gene therapy for control of seizures 298

Gene therapy for neuroprotection in epilepsy 299

Gene therapy for genetic forms of epilepsy 300

Gene therapy for multiple sclerosis 300

Gene therapy for relief of pain 301

Rationale of gene therapy for pain 301

Vectors for gene therapy of pain 301

Methods of gene delivery for pain 302

Endogenous analgesic production for cranial neuralgias 302

Gene delivery by intrathecal route 303

Gene transfer for delivery of analgesics to the spinal nerve roots 303

Gene therapy of peripheral neuropathic pain 304

Gene transfer by injections into the brain substance 305

Targets for gene therapy of pain 305

Zinc finger DNA-binding protein therapeutic for chronic pain 305

Gene therapy for producing enkephalin to block pain signals 305

Targeting nuclear factor-kB 306

Gene therapy targeted to neuroimmune component of chronic pain 306

Potential applications of gene therapy for management of pain 306

Concluding remarks on gene therapy for pain 307

Gene therapy for psychiatric disorders 308

Gene therapy for depression 308

Gene therapy for enhancing cognition after stress 308

Gene therapy against fear disorders 309

Companies involved in gene therapy of neurological disorders 309

7. Gene Therapy of Cardiovascular Disorders 311

Introduction 311

Techniques of gene transfer to the cardiovascular system 311

Direct plasmid injection into the myocardium 312

Catheter-based systems for vector delivery 312

Ultrasound microbubbles for cardiovascular gene delivery 313

Vectors for cardiovascular gene therapy 313

Adenoviral vectors for cardiovascular diseases 313

Plasmid DNA-based delivery in cardiovascular disorders 313

Intravenous rAAV vectors for targeted delivery to the heart 314

Hypoxia-regulated gene therapy for myocardial ischemia 314

Angiogenesis and gene therapy of ischemic disorders 314

Therapeutic angiogenesis vs vascular growth factor therapy 315

Gene painting for delivery of targeted gene therapy to the heart 315

Gene delivery to vascular endothelium 316

Targeted plasmid DNA delivery to the cardiovascular system with nanoparticles 316

Vascular stents for gene delivery 316

Gene therapy for genetic cardiovascular disorders 317

Genetic disorders predisposing to atherosclerosis 317

Familial hypercholesterolemia (FH) 317

Apolipoprotein E (apoE) deficiency 319

Hypertension 319

Genetic factors for myocardial infarction 320

Acquired cardiovascular diseases 320

Coronary artery disease with angina pectoris 320

Ad5FGF-4 320

Ischemic heart disease with myocardial infarction 321

Myocardial repair with IGF-1 therapy 322

Metalloproteinase-2 inhibitor gene therapy 322

Congestive heart failure 323

Rationale of gene therapy in CHF 323

Beta-ARKct gene therapy 323

Intracoronary adenovirus-mediated gene therapy for CHF 324

AAV-mediated gene transfer for CHF 324

AngioCell gene therapy for CHF 325

nNOS gene transfer in CHF 325

Cardiomyopathies 325

Cardiac conduction disturbances 326

Gene transfer approaches for biological pacemakers 326

Genetically engineered biological pacemakers 326

Gene therapy and heart transplantation 327

Peripheral arterial disease 327

Incidence and clinical features 327

Current management 328

Gene therapy for peripheral arterial disease 328

Angiogenesis by gene therapy 328

HIF-1a gene therapy for peripheral arterial disease 328

HGF gene therapy for peripheral arterial disease 329

Ischemic neuropathy secondary to peripheral arterial disease 329

Prevention of restenosis after angioplasty 330

Antisense approaches 330

Gene therapy to prevent restenosis after angioplasty 330

Techniques of gene therapy for restenosis 332

NOS gene therapy for restenosis 332

hTIMP-1 gene therapy to prevent intimal hyperplasia 333

Maintaining vascular patency after surgery 333

Companies involved in gene therapy of cardiovascular diseases 334

Future prospects of gene therapy of cardiovascular disorders 334

8. Gene therapy of viral infections 337

Introduction 337

Acquired Immunodeficiency Syndrome (AIDS) 337

Current management of AIDS 337

Gene therapy strategies in HIV/AIDS 338

HIV/AIDS vaccines 338

Insertion of protective genes into target cells. 339

Cell/gene therapies for HIV/AIDS 340

Transplantation of genetically modified T-cells 340

Transplantation of genetically modified hematopoietic cells 340

Anti-HIV ribozyme delivered in hematopoietic progenitor cells 341

Inhibition of HIV-1 replication by lentiviral vectors 341

VRX496 341

Intracellular immunization 342

Engineered cellular proteins such as soluble CD4s 342

Intracellular antibodies 342

Anti-rev single chain antibody fragment 342

Use of genes to chemosensitize HIV-1 infected cells 343

Autocrine interferon (INF)-b production by somatic cell gene therapy 343

Antisense approaches to AIDS 343

RNA decoys 343

Antisense oligodeoxynucleotides 343

RNA decoys 344

Ribozymes 344

RNAi applications in HIV/AIDS 345

siRNA-directed inhibition of HIV-1 infection 345

Role of the nef gene during HIV-1 infection and RNAi 345

Bispecific siRNA constructs 346

Targeting CXCR4 with siRNAs 346

Targeting CCR5 with siRNAs 346

Companies involved in developing gene therapy for HIV/AIDS 347

Conclusions regarding gene therapy of HIV/AIDS 348

Genetic vaccines for other viral infections 348

Cytomegalic virus infections 348

Viral hepatitis 349

Vaccine for hepatitis B virus 349

Vaccine for hepatitis C virus 350

Vaccine for herpes simplex virus 350

DNA vaccine against rabies 350

DNA vaccine for Ebola 351

Vaccines for avian influenza 351

Future prospects of DNA vaccines for avian influenza 352

Human trial of a DNA vaccine for avian influenza 353

Companies developing genetic vaccines for infections other than AIDS 353

9. Research, Development and Future of Gene Therapy 355

Basic research in gene therapy 355

R & D in gene therapy 355

Animal models of human diseases for gene therapy research 356

Lentiviral transgenesis 356

Financing research and development 356

Role of the NIH in gene therapy research 356

National Gene Vector Laboratories 356

Financing by the industry 357

Clinical trials in gene therapy 357

Clinical trials worldwide 357


To order this report:Biotechnology Industry: Gene Therapy - technologies, markets and companies

Biotechnology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!CONTACT:  Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Reportlinker Adds Molecular Diagnostics - Technologies, Markets and Companies
2. Reportlinker Adds Nanobiotechnologies- applications, markets and companies
3. Reportlinker Adds 2010 Membrane and Separation Technology Research Review
4. Reportlinker Adds Nanobiotechnology: Applications and Global Markets
5. Reportlinker Adds Chinese Markets for Biotechnology
6. Reportlinker Adds Merck KGaA: PharmaVitae Profile
7. Reportlinker Adds Global Bladder Cancer Therapeutics Industry
8. Reportlinker Adds Global Anticoagulants Industry
9. Reportlinker Adds Global Specialty Enzymes Industry
10. Reportlinker Adds Biomarkers - Technologies, Markets And Companies
11. Reportlinker Adds Next Generation U.S. and E.U. Biomaterials/BioMedical Devices: Market Trends & Commercial Implications
Post Your Comments:
(Date:10/7/2017)... ... October 06, 2017 , ... ... its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C ... software to perform Hi-C metagenome deconvolution using their own facilities, supplementing the ...
(Date:10/6/2017)... ... October 06, 2017 , ... The ... and technology sector at their fourth annual Conference where founders, investors, innovative practitioners ... and the ELEVATE pitch competition showcasing early stage digital health and med tech ...
(Date:10/5/2017)... ... , ... LabRoots , the leading provider of educational and interactive virtual ... to cancer research with a month-long promotion supporting the advancement of breast cancer research ... use promo code PinkRibbon to get 10 percent off their purchase of every the ...
(Date:10/5/2017)... ... October 05, 2017 , ... ... new applications of its Nanobind DNA/RNA extraction technology . Nanobind is a ... on the surface and that can be used for a wide variety of ...
Breaking Biology Technology:
(Date:7/20/2017)... Delta (NYSE: DAL ) customers now can use fingerprints instead ... National Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan Washington National Airport ... Delta,s biometric boarding pass experience that launched in ... the boarding process to allow eligible Delta SkyMiles Members who are enrolled ...
(Date:5/16/2017)... , May 16, 2017  Veratad Technologies, LLC ( ... online age and identity verification solutions, announced today they ... Conference 2017, May 15 thru May 17, 2017, in ... and International Trade Center. Identity impacts ... and in today,s quickly evolving digital world, defining identity ...
(Date:4/18/2017)... , April 18, 2017  Socionext Inc., a global expert in ... media edge server, the M820, which features the company,s hybrid codec ... provided by Tera Probe, Inc., will be showcased during the upcoming ... NAB show at the Las Vegas Convention ... Click ...
Breaking Biology News(10 mins):